These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 2659701)

  • 41. Vaccination of leprosy patients and healthy contacts.
    Samuel NM; Neupani K; Loudon J; Samuel S
    Indian J Lepr; 1985; 57(2):288-96. PubMed ID: 3908576
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh.
    Richardus RA; Butlin CR; Alam K; Kundu K; Geluk A; Richardus JH
    Vaccine; 2015 Mar; 33(13):1562-7. PubMed ID: 25701674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of Bacille Calmette-Guérin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis.
    Araujo Z; de Waard JH; de Larrea CF; Borges R; Convit J
    Vaccine; 2008 Oct; 26(44):5575-81. PubMed ID: 18723065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long lasting BCG protection against leprosy.
    Rodrigues LC; Kerr-Pontes LR; Frietas MV; Barreto ML
    Vaccine; 2007 Sep; 25(39-40):6842-4. PubMed ID: 17728023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size.
    Floyd S; Ponnighaus JM; Bliss L; Warndorff DK; Kasunga A; Mogha P; Fine PE
    Int J Tuberc Lung Dis; 2000 Dec; 4(12):1133-42. PubMed ID: 11144455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malaŵi. I. Methods of the vaccination phase.
    Pönnighaus JM; Fine PE; Bliss L; Gruer PJ; Kapira-Mwamondwe B; Msosa E; Rees RJ; Clayton D; Pike MC; Sterne JA
    Lepr Rev; 1993 Dec; 64(4):338-56. PubMed ID: 8127221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: a case-control study.
    Zodpey SP; Shrikhande SN; Kulkarni SW; Maldhure BR
    Indian J Public Health; 2007; 51(3):184-9. PubMed ID: 18229442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A seroepidemiological study of leprosy in high- and low-endemic Indonesian villages.
    Soebono H; Klatser PR
    Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):416-25. PubMed ID: 1890365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Research on BCG vaccination.
    ten Dam HG
    Adv Tuberc Res; 1984; 21():79-106. PubMed ID: 6433675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?
    Menzies D
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S71-4. PubMed ID: 11010826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Skin sensitization to mycobacteria amongst school children prior to a study of BCG vaccination in North Lebanon.
    Bahr GM; Stanford JL; Rook GA; Rees RJ; Frayha GJ; Abdelnoor AM
    Tubercle; 1986 Sep; 67(3):197-203. PubMed ID: 3775872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Failure of Mycobacterium leprae soluble antigens to suppress delayed-type hypersensitivity reaction to tuberculin.
    Fine PE; Gruer PJ; Maine N; Ponnighaus JM; Rees RJ; Stanford JL
    Clin Exp Immunol; 1989 Aug; 77(2):226-9. PubMed ID: 2673590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy.
    Bretscher PA
    Immunol Today; 1992 Sep; 13(9):342-5. PubMed ID: 1466750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and factors associated with tuberculosis infection among new school entrants, New York City, 1991-1993.
    Scholten JN; Fujiwara PI; Frieden TR
    Int J Tuberc Lung Dis; 1999 Jan; 3(1):31-41. PubMed ID: 10094167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies of vaccination of persons in close contact with leprosy patients in Argentina.
    Bottasso O; Merlin V; Cannon L; Cannon H; Ingledew N; Keni M; Hartopp R; Stanford C; Stanford J
    Vaccine; 1998 Jul; 16(11-12):1166-71. PubMed ID: 9682375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of an inverse association between tuberculosis infection and atopy: by T-cell-based immune assay (RD1-ELISpot).
    Soysal A; Bahçeciler N; Barlan I; Bakir M
    Pediatr Allergy Immunol; 2008 Dec; 19(8):709-15. PubMed ID: 18266833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the prevalence of tuberculosis infection in BCG vaccinated versus nonvaccinated school age children.
    Pulickal AS; Fernandez GV
    Indian Pediatr; 2007 May; 44(5):344-7. PubMed ID: 17536134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. The effect of dapsone treatment on the response to Mycobacterium leprae antigens, tuberculin purified protein derivative and non-mycobacterial stimulants.
    Reitan LJ; Closs O; Belehu A
    Int J Lepr Other Mycobact Dis; 1982 Dec; 50(4):455-67. PubMed ID: 6763003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine consisting of killed Mycobacterium leprae.
    Gill HK; Mustafa AS; Godal T
    Bull World Health Organ; 1986; 64(1):121-6. PubMed ID: 3524883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The significance of a dual skin test with PPD and PPD-B in humans after BCG vaccination.
    Landi S; Ashley MJ
    Dev Biol Stand; 1986; 58 ( Pt B)():631-6. PubMed ID: 3111907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.